The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of ...

A recent Andhra Pradesh health department study reveals a significant surge in alcohol-related liver, neurological, and ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

Jen Psaki announces new segment 'The Briefing with Jen Psaki' Tuesdays through Fridays at 9pm Eastern on MSNBC.

Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...

The firm's methods - using real human tissue samples in the lab - give drug developers a more accurate picture of how their ...

This week’s Truist Championship is up next in PGA TOUR Fantasy Golf presented by PGA TOUR Superstore, but before analysis and advice on how to proceed with the sixth Signature Event of the ...

Not so fast. While this is exciting news, semaglutide isn’t approved yet specifically for NASH or fatty liver disease—it’s currently approved for type 2 diabetes and used for weight loss.